MiNK Therapeutics (INKT) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MiNK Therapeutics (INKT) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 24.6% versus a loss of 62.1%. Over five years, INKT leads with a -90.8% price change compared with -99.5% for KLRS. Kalaris Therapeutics is the larger company by market cap ($59.5 million vs $56.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INKT | KLRS |
|---|---|---|
| Share price | $11.00 | $2.50 |
| Market cap | $56.13M | $59.51M |
| 1-day change | -3.68% | -2.34% |
| YTD return | -1.35% | -70.38% |
| 1-year return | -24.61% | -62.06% |
| 5-year return | -90.83% | -99.51% |
| EPS (TTM) | $-2.30 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $11.88 |
| 52-week low | $8.48 | $2.35 |
| Distance from 52-week high | -35.02% | -78.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +254.55% | +648.40% |
| Average volume | 13.80K | 252.88K |
| Shares outstanding | 5.10M | 23.80M |
| Employees | 15 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INKT has outperformed KLRS by 37.5 percentage points over the past year.
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Healthcare · Biotechnology · 15 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Healthcare · Biotechnology · 20 employees
INKT vs KLRS FAQ
Which is bigger, MiNK Therapeutics or Kalaris Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $59.51M compared with $56.13M for MiNK Therapeutics (INKT).
Which stock has performed better over the past year, INKT or KLRS?
INKT returned -24.61% over the past 12 months, compared with -62.06% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are MiNK Therapeutics and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.